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Most lymphocytes in the lamina propria of oral lichen planus (OLP) lesions express and secrete interferon-c (IFN-c)
and tumor necrosis factor-a (TNF-a), whereas they do not secret interleukin-4 and -10 or transforming growth
factor-b. We analyzed whether the polymorphisms of several cytokines may inﬂuence the susceptibility to OLP.
Cytokine typing was performed by a sequence-speciﬁc PCR assay. Thirteen cytokine genes with 22 single-
nucleotide polymorphisms were studied. IFN-c UTR 5644 genotype frequencies showed a signiﬁcant increase in
number of T/T homozygotes in OLP patients compared with controls (40.9 vs. 22.9%; p¼ 0.0022). Moreover, in OLP
patients, the frequency of the –308A TNF-a allele was higher than in the controls (21.6 vs. 9.3%; po 0.05) causing a
signiﬁcantly increased frequency of the genotype G/A in OLP (43.2 vs. 14.3%; p¼ 0.0002). Because in patients with
mucocutaneous lichen planus (LP), the frequency of the –308A TNF-a allele was more than double the values in the
pure OLP patients (40.9 vs. 15.1%; p¼ 0.003), the –308G/A TNF-a genotype showed a signiﬁcantly higher frequency
in patients with mucocutaneous LP than in patients with pure OLP (81.8 vs. 30.3%, p¼ 0.003). In conclusion, we
suggest that genetic polymorphism of the ﬁrst intron of the promoter gene of IFN-c may be an important risk factor
to develop oral lesions of LP, whereas an increase in the frequency of –308A TNF-a allele may best contribute to the
development of additional skin involvement.
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Lichen planus (LP) is a chronic inflammatory disease that
affects skin and mucous membranes of squamous cell
origin. LP probably represents a cell-mediated immunologic
response to an induced antigenic change in the skin or
mucosa, but the etiology is often unknown. The oral form of
lichen planus (OLP) seems more common, chronic, and
recalcitrant than the cutaneous type, persisting up to more
than 20 years without spontaneous remission (Scully et al,
2000). OLP is unlikely to be caused by a single antigen,
given that studies of T cell receptor-variable region genes
from lesional OLP T cells have not revealed the use of a
restricted number of different variable region genes (Tho-
mas et al, 1997). Probably, OLP is the common outcome of
the influence of a limited range of extrinsic antigens, altered
self-antigens, or superantigens. Although the majority of
intraepithelial lymphocytes in OLP are CD8þ cytotoxic T
cells, most lymphocytes in the lamina propria are CD4þ
helper T cells (Matthews et al, 1984; Ishii, 1987). These
subepithelial T cells have been seen to express interferon-g
(IFN-g) and tumor necrosis factor-a (TNF-a) and contain
mRNA for IFN-g and TNF-a and to secrete these cytokines
in vitro (Simark Mattsson et al, 1998, 1999). Contrarily, OLP
lesional T cells do not secrete interleukin-4 and -10 (IL-4, IL-
10) or transforming growth factor-b (TGF-b) (Simark Mattson
et al, 1998, 1999).
The basis of this Th1 cytokine bias in OLP is unclear. A
physiologic response to antigens or a dysregulation of the
immune response may be responsible.
Genetic influence could also play a role in the develop-
ment of OLP but immunogenetic studies of LP and OLP
have given controversial results, possibly owing to the
inclusion in the studies of patients heterogeneous for
etiology and pathogenesis (Carrozzo et al, 2001). Indeed,
cutaneous idiopathic LP is frequently associated with the
HLA-DR1 allele particularly the DRB10101 allele, whereas
idiopathic OLP or LP linked to liver disease is not (La Nasa
et al, 1995). Recently, hepatitis C virus-associated OLP
seems to represent a distinct variant, linked to the HLA-DR6
allele (Carrozzo et al, 2001).
Oral mucosal graft-versus-host disease (GVHD) closely
resembles OLP both clinically and histologically (Fujii et al,
1988; Mattsson et al, 1992). It is likely that graft-versus-host
disease and OLP share similar immunologic effector
mechanisms, resulting in T cell infiltration, basal keratino-
cyte apoptosis, epithelial basement membrane disruption,
and clinical disease (Sugerman et al, 2002). Although the
role of donor T cell activation in the induction of graft-
versus-host disease has been confirmed, there is evidence
suggesting that several cytokines are also involved (Ferrara,
1994). Very recently, a significant association between
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polymorphism of TNF-a, IFN-g, IL-10, and IL-6 and the
development of severe graft-versus-host disease has been
demonstrated (Middleton et al, 1998; Takahashi et al, 2000;
Cavet et al, 2001).
The aim of this study was to analyze whether the
polymorphisms of several pro- and anti-inflammatory
cytokines may influence the susceptibility to OLP in a
Northern-Italian population.
Results
Association of the IFN-a, TNF-a, and IL-4 polymorphism
with OLP No significant difference in the allele or genotype
frequencies of IL-1 and 10 cluster, IL-2, IL-6, IL-12, and
TGF-a were observed between the OLP subjects taken all
together and healthy controls (Tables I, II). In contrast, IFN-g
UTR 5644 genotype frequencies showed a significant
difference between cases and controls (p¼0.0022) (Table
I). This was due to an increased number of T/T homo-
zygotes in OLP patients compared with controls (40.9 vs.
22.9%), although no significant difference was noted in the
frequency of the T allele in OLP and controls (50 vs. 46.4%;
relative risk (rr)¼0.87, 95% confidence intervals (95% CI)
0.54–1.40, p40.05). In contrast, in OLP patients the
frequency of the –308A TNF-a allele was more than double
the value in the controls (21.6 vs. 9.3; rr¼ 2.69, 95% CI
1.41–5.15, po0.05). This caused a significantly increased
frequency of the genotype G/A in OLP compared to controls
(43.2 vs. 14.3%, p¼0.0002) (Table I). Also, we noted that
the frequency of the genotype G/G of the IL-4 –1098 is
more than sixfold higher in OLP than in controls (6.8 vs.
0.7%, p¼0.0427) (Table II) although no differences in the
allele frequencies were noted.
Patients with OLP are not associated with any HLA-DR
allele As already reported for other diseases (Wilson et al,
1993; Rood et al, 2000; Werth et al, 2000, 2002), we found
that only in OLP patients –308A TNF-a exhibit a linkage
disequilibrium with HLA-DR3 (Table III). A similar linkage
disequilibrium was also observed in OLP patients for the
allele HLA-DRB14 (Table III). All the OLP patients with at
least one HLA-DR3 or DR6 allele also possessed a –308A
TNF-a allele. We do not know whether each HLA-DR3 or
DR6 allele is on the same chromosomal strand as the –308A
TNF-a allele. This finding could indicate linkage disequili-
brium or an essential requirement for HLA-DR3 or DR6 to
occur with –308A TNF-a for disease to develop. (Table III).
When stratifying patients and controls according to HLA-
DR3 and DR6 status, the frequency of individuals with at
least one –308A TNF-a allele was still significantly higher in
HLA-DR3- and HLA-DR6-negative OLP patients than in
controls (27 vs. 8%; rr¼3.48, 95%, CI 1.58–7.69, p¼0.002;
and 39 vs. 17%, rr¼2.22, 95% CI 1.29–3.83, p¼0.008,
respectively) (Table III). Moreover, no significant difference
was observed between OLP subjects taken all together and
healthy controls (Table IV) and between the pure OLP or
mucocutaneous LP groups compared separately with
controls (data not shown) regarding the HLA-DR allele
frequency. This was already observed in previous studies
(La Nasa et al, 1995; Carrozzo et al, 2001).
TNF-a polymorphism is different in patients with
exclusive oral lesions and in patients with mucocuta-
neous involvement The –308G/A TNF-a genotype showed
a significantly higher frequency in patients with mucocuta-
neous LP than in patients with pure OLP (Table V). This was
due to the fact that in patients with mucocutaneous LP, the
frequency of the –308A TNF-a allele was more than double
the values in the pure OLP patients (40.9 vs. 15.1%,
rr¼3.88, 95% CI 1.31–11.46, p¼0.003). Conversely, we
found no significant differences between pure OLP and
mucocutaneous LP for any other cytokine (data not shown).
Finally, between the OLP subjects with erosive lesions
compared with healthy controls, no significant differences
were observed in the allele or genotype frequencies for any
cytokine analyzed (data not shown).
Discussion
Many studies have suggested a central role for TNF-a and
IFN-g in the pathogenesis of OLP (Yamamoto et al, 1994;
Sugerman et al, 1996; Younes et al, 1996; Fayyazi et al,
1999), but this is the first study showing that genetic
variations in expression of both these cytokines contribute
to susceptibility to OLP and may influence the course of the
disease.
Analyzing jointly the polymorphisms of several pro- and
anti-inflammatory cytokines, we found that the OLP patients
had a significantly higher frequency of the T/T genotype
within the first intron of IFN-g gene promoter and of the A
allele at the –308 TNF-a polymorphism. Notably, both the
observed polymorphisms are known to increase the
production of the respective cytokine (Bouma et al, 1996;
Wilson et al, 1997; Louis et al, 1998; Perrey et al, 1998;
Galbraith et al, 1998; Pravica et al, 1999; Hoffmann et al,
2001; Braun et al, 1996).
Significantly, many other studies demonstrate a high
level of IFN-g and TNF-a in involved oral mucosa (Fayyazi
et al, 1999) and in the serum of patients with OLP (Urata
et al, 1986; Yamamoto et al, 1991; Karagouni et al, 1994).
Both infiltrating T lymphocytes and mast cells in OLP
contain IFN-g and TNF-a mRNA (Walsh et al, 1995; Zhao
et al, 2001), confirming the hypothesis that a delayed-type
hypersensitivity (Th1) reaction is responsible for the devel-
opment of OLP. Indeed, oral keratinocytes also demonstrate
unregulated TNF-a mRNA in a pattern identical to that seen
in cutaneous delayed-type hypersensitivity reaction (Suger-
man et al, 1996). Conversely, OLP lesional T cells did not
secrete IL-4 and IL-10 or TGF-b (Simark Mattson et al,
1998, 1999). Our study suggests that this Th1 cytokine bias
could be genetically induced and influence OLP suscept-
ibility. Because the TNF-a gene is located in the class III
region of HLA on the short arm of chromosome 6, there was
the possibility that the difference observed in this study was
due to the linkage disequilibrium of TNF-a with some HLA
alleles, despite the inconsistency of the immunogenetic
studies on OLP (Carrozzo et al, 2001). We found the less
common –308A TNF-a allele associated with HLA-DR3 and
DR6 (DRB114) in OLP patients. The linkage disequilibrium
of the –308A TNF-a promoter polymorphism with HLA-DR3
is well known in Caucasian persons with skin diseases as
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Table I. IL-1 cluster, IL-12, IFN-c, TGF-b, and TNF-a polymorphisms in OLP patients and controls
Genotype OLP, n¼44 (a) Controls, n¼ 140 (a) Relative risk 95% CI
IL1a –889
C/C 28 (63.6) 73 (52.1) 1.61 0.80–3.23
T/C 12 (27.3) 54 (38.6) 0.60 0.28–1.26
T/T 4 (9.1) 13 (9.3) 0.98 0.30–3.17
IL-1b –511
C/C 16 (36.4) 70 (50) 0.57 0.28–1.15
C/T 20 (45.4) 58 (42.4) 1.18 0.60–2.33
T/T 8 (18.2) 12 (8.6) 2.37 0.90–6.24
IL-1b þ3962
C/C 22 (50) 76 (54.3) 0.84 0.43–1.66
C/T 21 (47.7) 56 (40) 1.37 0.69–2.71
T/T 1 (2.3) 8 (5.7) 0.38 0.05–3.16
IL-1R pst1 1970
C/C 19 (43.2) 60 (42.9) 1.01 0.51–2.01
C/T 19 (43.2) 67 (47.9) 0.83 0.42–1.64
T/T 6 (13.6) 13 (9.2) 1.54 0.55–4.33
IL-1RA mspa1 11100
C/C 1 (2.3) 4 (2.9) 0.79 0.09–7.27
T/C 18 (40.9) 57 (40.7) 1.01 0.51–2.01
T/T 25 (56.8) 79 (56.4) 1.02 0.51–2.01
IL-12 –1188
A/A 24 (54.5) 73 (52.1) 1.10 0.56–2.17
C/A 18 (40.9) 57 (40.7) 1.01 0.51–2.01
C/C 2 (4.5) 10 (7.2) 0.62 0.13–2.94
IFN-g UTR 5644
A/A 18 (40.9) 42 (30) 1.62 0.80–3.26
A/T 8 (18.2) 66 (47.1) 0.25 0.11–0.57
T/Ta 18 (40.9) 32 (22.9) 2.34 1.14–4.79
TGF-b1 cdn 10
C/C 14 (31.8) 32 (22.9) 1.58 0.75–3.32
C/T 21 (47.7) 63 (45) 1.12 0.57–2.20
T/Tb 9 (20.4) 45 (32.1) 0.54 0.24–1.23
TGF-b1 cdn 25
C/C 1 (2.3) 4 (2.9) 0.79 0.09–7.27
C/G 8 (18.2) 14 (10) 2.00 0.78–5.14
G/G 35 (79.5) 122 (87.1) 0.57 0.24–1.39
TNF-a –308
A/A 0 (0) 3 (2.1) — —
G/Ab 19 (43.2) 20 (14.3) 4.56 2.13–9.77
G/G 25 (56.8) 117 (83.6) 0.26 0.12–0.55
TNF-a –238
A/A 0 (0) 1 (0.7) — —
G/Ac 3 (6.8) 19 (13.6) 0.47 0.13–1.66
G/G 41 (93.2) 120 (85.7) 2.28 0.64–8.06
aData are reported as number (%)
b,cp¼ 0.0022, p¼ 0.0002.
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Table II. IL-2, IL-4 cluster, IL-6, and IL-10 polymorphisms in OLP patients and controls
Genotype OLP (n¼44)a Controls (n¼ 140)a Relative risk 95% CI
IL-2 –330
G/G 5 (11.4) 17 (12.1) 0.93 0.32–2.68
T/G 19 (43.2) 61 (43.6) 0.98 0.50–1.95
T/T 20 (45.4) 62 (44.3) 1.05 0.53–2.07
IL-2 þ 166
G/G 27 (61.4) 86 (61.4) 1.00 0.50–2.00
G/T 13 (29.5) 45 (32.1) 0.89 0.42–1.85
T/T 4 (9.1) 9 (6.5) 1.46 0.43–4.98
IL-4 –1098
G/Gb 3 (6.8) 1 (0.7) 10.17 1.03–100.42
T/G 5 (11.4) 23 (16.4) 0.65 0.23–1.83
T/T 36 (81.8) 116 (82.9) 0.93 0.38–2.25
IL-4 –590
C/C 35 (79.5) 110 (78.6) 1.06 0.46–2.45
C/T 7 (15.9) 28 (20) 0.76 0.31–1.88
T/T 2 (4.6) 2 (1.4) 3.29 0.45–24.04
IL-4 –33
C/C 37 (84.1) 105 (75) 1.76 0.72–4.31
C/T 6 (13.6) 32 (22.9) 0.53 0.21–1.37
T/T 1 (2.3) 3 (2.1) 1.06 0.11–10.48
IL-4RA þ 1902
A/A 29 (65.9) 95 (67.9) 0.92 0.45–1.88
G/A 13 (29.5) 38 (27.1) 1.13 0.53–2.38
G/G 2 (4.6) 7 (5) 0.90 0.18–4.52
IL-6 –174
C/C 6 (13.6) 13 (9.3) 1.54 0.55–4.33
C/G 17 (38.7) 70 (50) 0.63 0.32–1.26
G/G 21 (47.7) 57 (40.7) 1.33 0.67–2.63
IL-6 nt 565
A/A 7 (15.9) 13 (9.3) 1.85 0.69–4.97
G/A 16 (36.4) 67 (47.8) 0.62 0.31–1.25
G/G 21 (47.7) 60 (42.9) 1.22 0.62–2.40
IL-10 –1082
A/A 16 (36.4) 47 (33.6) 1.13 0.56–2.29
G/A 23 (52.3) 76 (54.3) 0.92 0.47–1.82
G/G 5 (11.4) 17 (12.1) 0.93 0.32–2.68
IL-10 –819
C/C 20 (45.4) 70 (50) 0.83 0.42–1.64
C/T 17 (38.6) 62 (44.3) 0.79 0.40–1.58
T/T 7 (15.9) 8 (5.7) 3.12 1.06–9.17
IL-10 –592
A/A 7 (15.9) 8 (5.7) 3.12 1.06–9.17
C/A 17 (38.7) 62 (44.3) 0.79 0.40–1.58
C/C 20 (45.4) 70 (50) 0.83 0.42–1.64
aData are reported as number (%).
bp¼ 0.0427.
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subacute cutaneous and systemic lupus erythematosus
and dermatomyositis (Rood et al, 2000; Werth et al, 2000;
Werth et al, 2002). Notably, in a small study, a significant
association between erosive OLP and HLA-DR3 has been
reported (Jontell et al, 1987), whereas hepatitis C virus-
associated OLP has been related to HLA-DR6 (Carrozzo et
al, 2001). Nevertheless, we found no significant association
between HLA-DR and OLP patients without hepatitis C virus
infection independently of the presence of erosive or skin
lesions. Moreover, the –308A TNF-a association with OLP
was still significant in HLA-DR3- and HLA-DR6-negative
individuals.
Another interesting result of the present study is that
cytokine polymorphism may also influence the clinical
Table III. Linkage disequilibria for TNF-a in OLP patients and controls
Genotypes þ /þ a þ /a /þ a /a v2 Drelative
OLP patients
–308 A/HLA-DR3 7 (16) 12 (27) 0 (0) 25 (57) 10.95 1.00
–308 A/HLA-DR6b 2 (4) 17 (39) 0 (0) 25 (57) 2.76 1.00
Controls
–308 A/HLA-DR3 11 (10) 9 (8) 9 (8) 86 (75) 23.84 0.46
–308 A/HLA-DR6b 0 (0) 20 (17) 4 (3) 91 (79) 0.87 – 0.0038
aData are presented as number (%).
bHLA-DRB114.
Table IV. Frequencies of HLA-DR alleles in controls and patients affected by OLPa
HLA-DRB gene OLP (n¼ 44)b Controls (n¼ 115)b,c Relative risk 95% CI
DR01 11 (25) 20 (17.4) 1.58 0.69–3.65
DR02 10 (22.7) 24 (20.9) 1.11 0.48–2.57
DR03 7 (15.9) 23 (20) 0.75 0.29–1.91
DR04 7 (15.9) 19 (16.5) 0.95 0.37–2.46
DR05 18 (40.9) 56 (48.7) 0.72 0.36–1.47
DR06 9 (20.4) 31 (27) 0.69 0.30–1.61
13d 7 (15.9) 18 (24.8) 1.02 0.39–2.64
14 2 (4.5) 4 (3.5) 1.32 0.23–7.48
DR07 16 (36.4) 29 (25.2) 1.69 0.80–3.56
DR08 3 (6.8) 8 (7) 0.97 0.24–3.87
DR09 0 (0) 0 (0) — —
DR10 3 (6.8) 3 (2.6) 2.73 0.53–14.08
aAll the comparisons were not significant.
bData are reported as number (%).
cOnly 115 controls were available for HLA analysis.
dAsterisk Indicates the splits of the broad antigen.
TableV. TNF-a polymorphisms in mucocutaneous LP and pure OLP patients
Genotype Mucocutaneous LP (n¼11)a Pure OLP (n¼33)a Relative risk 95% CI
TNF-a –308
A/A 0 (0) 0 (0) — —
G/A 9 (81.8%) 10 (30.3) 10.35 1.89–56.80b
G/G 2 (18.2%) 23 (69.7) 0.10 0.02–0.53
aData are presented as number (%).
bp¼ 0.003.
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presentation of the disease. Up to 44% of patients with OLP
are prone to develop cutaneous lesions (Eisen, 1999) but it
is unknown why this happens. We found that the OLP
patients with skin involvement presented the –308 TNF-a G/
A genotype with significantly higher percentage (82%) than
patients with exclusive oral lesions (30%), suggesting that
the joint presence of cutaneous lesions could be caused by
higher TNF-a production. Most of our patients were
followed for more than 6 years and clinically considered to
be affected by mucocutaneous LP if during the periodical
check skin lesions were either confirmed by biopsy or
evaluated by a dermatologist. Although some of the OLP
patients studied could in theory develop cutaneous lesions
in future, a recent large report found that the development
of cutaneous lesions preceded the onset of mucosal
lesions, usually by 1 y, whereas cutaneous lichen planus
followed the appearance of oral lesions only in a minority of
cases, normally within several months (Eisen, 1999).
TNF-a and IFN-g are thought to induce keratinocyte
expression of ICAM-1 in LP (Konter et al, 1990). Interest-
ingly, TNF-a and IFN-g has been reported to synergistically
increase ICAM-1 expression only in skin keratinocytes,
whereas in oral keratinocytes the increase of ICAM-1
expression with TNF-a and IFN-g was not greater than
when stimulated with IFN-g alone (Li et al, 1996).
The whole data suggest that greater IFN-g production
linked to genetic polymorphism of the promoter gene could
be an important risk factor to develop OLP lesions, whereas
the joint (or single) presence of genetically determined high
TNF-a production could be involved in the onset of
cutaneous lesions. Moreover, the genetically determined
higher production of IFN-g could be responsible for the
characteristic chronic outcome of the oral lesions. Further
studies focused on patients with exclusive skin lesions are
clearly warranted.
We also noted a significantly increased frequency of the
genotype C/C of the –33 IL-4 in OLP. Notably, the
frequencies of genotypes T/T and A/A of the –819 and –
592 IL-10 (indicating low IL-10 producers; Hoffmann et al,
2001) were increased too in OLP, but probably owing to the
small number of cases, there were statistically insignificant
(Table II). Apparently, OLP-lesional T cells do not secrete IL-
4 and IL-10 in vitro (Simark Mattsson et al, 1998, 1999), and
the observed polymorphisms could represent a sign of
suppressed function. Unfortunately, there are no data on the
functional significance of the above polymorphism of IL-4
and because of the low numbers, definite conclusions
cannot be drawn.
In conclusion, we suggest that the Th1 cytokine bias seen
in OLP is the result of genetic dysregulation of the immune
response rather than a physiologic response to antigens.
Particularly, we found that genetic polymorphism of the first
intron of the promoter gene of IFN-gmay be an important risk
factor to develop oral lesions of LP, whereas an increase in
the frequency of –308A TNF-a allele may contribute to the
development of additional skin involvement.
Materials and Methods
Patients Forty-four unrelated Caucasian patients (23 women and
21 men, median age 56.5 y, range 27–77 y) with OLP took part in
the study. All patients had oral bilateral reticular lesions usually
affecting the buccal mucosa. In each case the clinical diagnosis
was confirmed histologically. No patient was suspected to have
drug or restoration related lichenoid lesions, and no patient
showed histologic signs of dysplasia. No patient had evidence of
chronic hepatitis C evaluated as described in detail elsewhere
(Carrozzo et al, 1996). The patients were followed for a median time
of 78.5 mo and clinically reassessed at each check. A history of
cutaneous lichen planus was obtained from each patient and
considered positive only if confirmed by biopsy or evaluation by a
dermatologist. The patients were classified as affected by pure
OLP if they had had exclusive oral lesions during the entire follow-
up time. Thirty-three patients had pure OLP. Eleven patients had (or
had a history of) a combination of oral and cutaneous lesions of LP
(mucocutaneous LP), the latter usually represented by papules
around the flexor surface of the forearms. Fourteen patients
showed erosive oral lesions during the follow-up time.
As controls, 140 healthy unrelated donors serologically typed for
HLA-A and B and without evidence or history of LP were studied.
Patients and controls were all Italian and their geographic origin
had been carefully checked to compare subjects from the same
areas. Informed consent and University of Turin ethical committee
approval were obtained before the study started.
HLA DRB typing DNA was isolated from whole peripheral blood
collected with ethylenediaminetetraacetic acid using a microsalting
out method (Miller et al, 1988) or an automatic apparatus (Genomic
DNA Extraction, Talent s.r.l.). For intermediate-resolution DRB1
typing, locus-specific amplification was performed using primer
pairs designed to amplify the entire exon 2 of the locus as
previously published (Carrozzo et al, 2001).
Cytokine genotyping Cytokine typing was performed by a
sequence-specific PCR assay. The sequence-specific PCR tray
kits were supplied by Heidelberg University and used standard
amplification and detection conditions, enabling rapid and cost-
efficient analysis of multiple polymorphisms (Neben et al, 2002);
each typing tray contained (for one typing) 48 PCR mixes
distributed and lyophilized in PCR trays. Amplification was carried
out using a PCR 9600 apparatus (Applied Biosystems, Foster City,
CA) under the following conditions: initial denaturation 941C, 2 min;
denaturation 941C, 10 s; annealingþ extension 651C, 1 minute (10
cycles); denaturation 941C, 10 s; annealing 611C, 50 s; and
extension 721C, 30 s (20 cycles). The kit was reproducible and easy
to use, as also confirmed by preliminary results of the 13th
International Histocompatibility Workshop (personal communica-
tion from the workshop co-coordinators).
The absence or presence of PCR products was visualized by 2%
agarose gel electrophoresis. After electrophoresis, the gel was
placed on a UV transilluminator and a Polaroid picture for
interpretation and documentation was taken. As a control, each
of the primer mixes contained a primer pair which amplifies either a
part of the b-globin gene or a part of C-reactive protein gene. The
b-globin control primers produce an 89-bp fragment, whereas the
primers amplifying the C-reactive protein gene produce a 440-bp
amplicon.
The allele and genotype frequencies of the following cytokine
genes have been determined: IL-1a (T/C –889), IL-1a (C/T –511, T/
C þ 3962), IL-12 (C/A –1188), IFN-g (A/T UTR 5644), TGF-a (C/T
codon 10, G/C codon 25), TNF-a (G/A –308, G/A –238), IL-2 (T/G –
330, G/T þ 166), IL-4 (T/G –1098, T/C –590, T/C –33), IL-6 (G/C –
174, G/A nt 565), IL-10 (G/A –1082, C/T –819, C/A –592), IL-1R (C/
T pst1 1970), IL-1RA (T/C mspa111100), and IL-4RA (G/A –1902).
Statistical analysis Allele frequencies were estimated by direct
gene counting. To test the Hardy–Weinberg equilibrium, observed
and expected frequencies of the various genotypes were com-
pared using the chi-square test. A p value of less than 0.05 was
considered statistically significant. The chi-square test was
also used for linkage disequilibrium analysis where linkage
92 CARROZZO ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
disequilibrium coefficients (D) were calculated from phenotypes of
the less common allele, as described in Mattiuz et al (1970).
Relative linkage disequilibria (Drelative) were calculated dividing the
linkage disequilibrium coefficient (D) by D maximum (Lewontin,
1964), which is the value of the maximum linkage disequilibrium
compatible with the frequencies of the alleles originating the
disequilibrium. For HLA statistical analysis, patients were grouped
according to the presence of exclusive oral involvement or
mucocutaneous lesions (pure OLP and mucocutaneous LP,
respectively). HLA allele frequencies were compared using a
standard Woolf–Haldane analysis (Svejgaard et al, 1974). Prob-
ability values obtained were corrected (p corrected) for the number
of comparisons. A corrected p value of less than 0.05 was
considered statistically significant.
This work was supported by MURST (ex quota 60%) and the
Department of Biomedical Sciences and Human Oncology, University
of Turin.
DOI: 10.1046/j.0022-202X.2003.22108.x
This paper is dedicated to the Memory of Prof. Emilio Sergio Curtoni
Manuscript received February 27, 2003; revised June 12, 2003;
accepted for publication September 16, 2003
Address correspondence to: Marco Carrozzo, Clinica Odontostoma-
tologica, C.so Dogliotti 14, I-10126 Torino, Italy. Email: marco.
carrozzo@unito.it
References
Bouma G, Xia B, Crusius JB, et al : Distribution of four polymorphisms in the
tumour necrosis factor (TNF) genes in patients with inflammatory bowel
disease (IBD). Clin Exp Immunol 103:391–396, 1996
Braun N, Michel U, Ernst BP, Metzner R, Bitsch A, Weber F, Rieckmann P: Gene
polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-
alpha) in multiple sclerosis and its influence on the regulation of TNF-
alpha production. Neurosci Lett 215:75–78, 1996
Carrozzo M, Francia di Celle P, Gandolfo S, et al: Increased frequency of HLA-
DR6 allele in Italian patients with hepatitis C virus associated oral lichen
planus. Br J Dermatol 144:803–808, 2001
Carrozzo M, Gandolfo S, Carbone M, Colombatto P, Broccoletti R, Garzino P,
Ghisetti V: Hepatitis C virus infection in Italian patients with oral lichen
planus: A prospective case-control study. J Oral Pathol Med 25:527–533,
1996
Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG:
Interferon-gamma and interleukin-6 gene polymorphisms associate with
graft-versus-host disease in HLA-matched sibling bone marrow trans-
plantation. Blood: 98:1594–1560, 2001
Eisen D: The evaluation of cutaneous, genital, scalp, nail, esophageal, and ocular
involvement in patients with oral lichen planus. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod 88:431–436, 1999
Fayyazi A, Schweyer S, Soruri A, et al: T lymphocyte and altered keratinocyte
express interferon-gamma and interleukin 6 in lichen planus. Arch
Dermatol Res 291:485–490, 1999
Ferrara JLM: Paradigm shift for graft-versus-host disease. Bone Marrow
Transplant 14:183–184, 1994
Fujii H, Ohashi M, Nagura H: Immunohistochemical analysis of oral lichen-planus-
like eruption in graft-versus-host disease after allogeneic bone marrow
transplantation. Am J Clin Pathol 89:177–186, 1988
Galbraith GM, Steed RB, Sanders JJ, Pandey JP: Tumor necrosis factor alpha
production by oral leukocytes. Influence of tumor necrosis factor
genotype. J Periodontol 169:428–433, 1998
Hoffmann SC, Stanley EM, Cox ED, et al: Association of cytokine polymorphic
inheritance, in vitro cytokine production in anti-CD3/CD28-stimulated
peripheral blood lymphocytes. Transplantation 72:1444–1450, 2001
Ishii T: Immunohistochemical demonstration of T cell subsets and accessory cells
in oral lichen planus. J Oral Pathol 16:356–361, 1987
Jontell M, Stahlblad PA, Rosdahl I, Lindblom B: HLA-DR3 antigens in erosive oral
lichen planus, cutaneous lichen planus, and lichenoid reactions. Acta
Odontol Scand 45:309–312, 1987
Karagouni EE, Dotsika EN, Sklavounou A: Alteration in peripheral blood
mononuclear cell function and serum cytokines in oral lichen planus. J
Oral Pathol Med 23:28–35, 1994
Konter U, Kellner I, Hoffmeister B, Sterry W: Induction and upregulation of
adhesion receptors in oral and dermal lichen planus. J Oral Pathol Med
19:459–463, 1990
La Nasa G, Cottoni F, Mulargia M, et al: HLA antigen distribution in different
clinical subgroups demonstrates genetic heterogeneity in lichen planus.
Br J Dermatol 132:897–900, 1995
Lewontin RC: The interaction of selection and linkage: General considerations of
heterotic models. Genetics 49:49–67, 1964
Li J, Mahiouz DL, Farthing PM, Haskard DO, Thornhill MH: Heterogeneity of
ICAM-1 expression, and cytokine regulation of ICAM-1 expression, in
skin and oral keratinocytes. J Oral Pathol Med 25:112–118, 1996
Louis E, Franchimont D, Piron A, et al: Tumour necrosis factor (TNF) gene
polymorphism influences TNF-alpha production in lipopolysaccharide
(LPS) -stimulated whole blood cell culture in healthy humans. Clin Exp
Immunol 113:401–406, 1998
Matthews JB, Scully CM, Potts AJ: Oral lichen planus: An immunoperoxidase
study using monoclonal antibodies to lymphocyte subsets. Br J Dermatol
111:587–595, 1984
Mattiuz PL, Ihde D, Piazza A, Cappellini R, Bodmer WDM: New approaches to
population genetic and segregation analysis of the HLA system. In:
Terasaki PI (ed). Histocompatibility Testing. Copenhagen: Munksgaard,
1970; p 193–205
Mattsson T, Sundqvist KG, Heimdahl A, Dahllof G, Ljungman P, Ringden O: A
comparative immunological analysis of the oral mucosa in chronic graft-
versus-host disease and oral lichen planus. Arch Oral Biol 37:539–547,
1992
Middleton PG, Taylor PRA, Jackson G, Proctor SJ, Dickinson AM: Cytokine gene
polymorphisms associated with severe acute graft-versus-host disease
in HLA-identical sibling transplants. Blood :3943–3948, 1998
Miller SA, Dykes DD, Polesky HF: A simple salting-out procedure for extraction
DNA from human nucleated cells. Nucleic Acids Res 16:221–228, 1988
Neben K, Mytilineos J, Moehler TM, et al: Polymorphisms of the tumor necrosis
factor-alpha gene promoter predict for outcome after thalidomide therapy
in relapsed and refractory multiple myeloma. Blood 100:2263–2265, 2002
Perrey C, Pravica V, Sinnott PJ, Hutchinson JV: Genotyping for polymorphism in
interferon g, interleukin 10, transforming growth factor b1 and tumour
necrosis factor a gene: A technical report. Transpl Immunol 6:193–197,
1998
Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV: In vitro
production of IFN-gamma correlates with CA repeat polymorphism in the
human IFN-gamma gene. Eur J Immunogenet 26:1–3, 1999
Rood MJ, van Krugten MV, Zanelli E, et al: TNF-308A and HLA-DR3 alleles
contribute independently to susceptibility to systemic lupus erythemato-
sus. Arthritis Rheum 43:129–134, 2000
Scully C, Eisen D, Carrozzo M: The management of oral lichen planus. Am J Clin
Dermatol 1:287–306, 2000
Simark-Mattsson C, Jontell M, Bergenholtz G, Heyden M, Dahlgren UI:
Distribution of interferon-gamma mRNA-positive cells in oral lichen
planus lesions. J Oral Pathol Med 27:483–488, 1998
Simark-Mattsson C, Bergenholtz G, Jontell M et al: Distribution of interleukin-2-4-
10, tumour necrosis factor-alpha and transforming growth factor-beta
mRNAs in oral lichen planus. Arch Oral Biol 44:499–507, 1999
Sugerman PB, Savage NW, Seymour GJ, Walsh LJ: Is there a role for tumor
necrosis factor-alpha (TNF-alpha) in oral lichen planus? J Oral Pathol Med
25:219–224, 1996
Sugerman PB, Savage NW, Walsh LJ, et al: The pathogenesis of oral lichen
planus. Crit Rev Oral Biol Med 13:350–365, 2002
Svejgaard A, Jersild C, Staub Nielsen L, Bodmer WF: HLA antigens and disease.
Statistical and genetical considerations. Tissue Antigens 4:95–105, 1974
Takahashi H, Furukawa T, Hashimoto S, et al: Contribution of TNF-alpha and IL-
10 gene polymorphisms to graft-versus-host disease following allo-
hematopoietic stem cell transplantation. Bone Marrow Transplant 26:
1317–1323, 2000
Thomas DW, Stephens P, Stephens M, Patten DW, Lim SH: T-cell receptor V beta
usage by lesional lymphocytes in oral lichen planus. J Oral Pathol Med
26:105–109, 1997
Urata M, Yoshida H, Yanagawa T, et al: Interferon activity and its characterization
in the sera of patients with premalignant lesions arising in oral mucosa. Int
J Oral Maxillofac Surg 15:134–147, 1986
Walsh LJ, Davis MF, Xu LJ, Savage NW: Relationship between mast cell
degranulation and inflammation in the oral cavity. J Oral Pathol Med
24:266–272, 1995
OLP AND CYTOKINE POLYMORPHISMS 93122 : 1 JANUARY 2004
Werth VP, Callen JP, Ang G, Sullivan K: Association of tumor necrosis factor-a and
HLA polymorphisms with adult dermatomyositis: Implications for a
unique pathogenesis. J Invest Dermatol 119:617–620, 2002
Werth VP, Zhang W, Dortzbach K, Sullivan K: Association of a promoter
polymorphism of tumor necrosis factor-a with subacute cutaneous lupus
erythematosus and distinct photoregulation of transcription. J Invest
Dermatol 115:726–730, 2000
Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW: An
allelic polymorphism within the human tumor necrosis factor alpha
promoter region is strongly associated with HLA A1, B8, and DR3 alleles.
J Exp Med 177:557–560, 1993
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a
polymorphism in the human tumor necrosis factor alpha promoter on
transcriptional activation. Proc Natl Acad Sci USA 94:3195–3199, 1997
Yamamoto T, Osaki T, Yoneda K, Ueta E: Cytokine production by keratinocytes
and mononuclear infiltrates in oral lichen planus. J Oral Pathol Med
23:309–315, 1994
Yamamoto T, Yoneda K, Ueta E, Hirota J, Osaki T: Serum cytokine levels in
patients with oral mucous membrane disorders. J Oral Pathol Med
20:275–279, 1991
Younes F, Quartey EL, Kiguwa S, Partridge M: Expression of TNF and the 55-kDa
TNF receptor in epidermis, oral mucosa, lichen planus and squamous cell
carcinoma. Oral Dis 2:25–31, 1996
Zhao ZZ, Sugerman PB, Zhou XJ, Walsh LJ, Savage NW: Mast cell degranulation
and the role of T cell RANTES in oral lichen planus. Oral Dis 7:246–251,
2001
94 CARROZZO ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
